EUVIMEDEUVIMED entdecken
Multizentrische Studie

A multicenter study on the use of purified cannabidiol for children with treatment-resistant developmental and epileptic encephalopathies

Gabriela Reyes Valenzuela, Alberto Espeche, Sebastian Fortini, Beatriz Gamboni, Javier Adi, Marco Semprino, Lorena Fasulo, Santiago Galicchio, Pedro Cachia, Santiago Chacón, Agustin Calvo, Lucas Beltran und 2 weitere

Epilepsy & Behavior · 2025

DOI: 10.1016/j.yebeh.2025.110590 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Epilepsy & Behavior, 2025. Verfasst von Gabriela Reyes Valenzuela und 13 weiteren Autor:innen. Beteiligte Einrichtung: Hospital de Pediatría Prof. Dr. Juan P Garrahan, Buenos Aires, Argentina. Hauptthemen laut MEDLINE: Cannabidiol, Drug Resistant Epilepsy, Anticonvulsants. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: This descriptive, real-world, multicenter study aimed to evaluate the efficacy, safety, and tolerability of purified cannabidiol (CBD) as an add-on therapy in children with treatment-resistant developmental and epileptic encephalopathies (DEE). METHODS: Children aged 0.5 to 16 years who met the International League against Epilepsy (ILAE) criteria for drug-resistant DEE and were treated with purified CBD at 10 different centers between March 2021 and December 2024 were included. RESULTS: A total of 551 patients were enrolled. The mean age at CBD initiation was 8.5 years (SD 5 years; range 0.5-18). Median follow-up duration was 22 months (range 13-32). Etiologies were structural in 249 (45 %), genetic in 160 (28.8 %), immune-mediated in five (0.9 %), infectious in three (0.5 %), and unknown in 134 (24.3 %). After 12-32 months of follow-up, 279 patients (50.6 %) had a > 50 % reduction in seizure frequency, including 78 (14.2 %) who became seizure-free. A reduction of 50 % reduction in seizures and 56 (10.2 %) remaining seizure-free. CONCLUSIONS: This study supports the use of purified CBD as an effective, safe, and well-tolerated treatment option for children with drug-resistant DEEs of diverse etiologies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CannabidiolDrug Resistant EpilepsyAnticonvulsantsHumansChildChild, PreschoolMaleFemaleAdolescentInfantTreatment OutcomeFollow-Up Studies

Stichwörter der Autor:innen

Adverse eventsCannabidiolDevelopmentalEfficacyEpileptic encephalopathy

Substanzen

CannabidiolAnticonvulsants

Autor:innen und Institutionen

  • Hospital de Pediatría Prof. Dr. Juan P Garrahan, Buenos Aires, Argentina.
  • Hospital Público Materno Infantil, Salta, Argentina.
  • Hospital del Niño Jesús, Tucuman, Argentina.
  • Hospital Pediátrico Humberto H Notti, Mendoza, Argentina.
  • Clínica San Lucas, Neuquen, Argentina.
  • Hospital de Niños Victor J Vilela, Rosario, Santa Fé, Argentina.

Zitieren

APA

Reyes Valenzuela, G., Espeche, A., Fortini, S., Gamboni, B., Adi, J., Semprino, M., Fasulo, L., Galicchio, S., Cachia, P., Chacón, S., Calvo, A., Beltran, L., Bautista, C., & Caraballo, R. H. (2025). A multicenter study on the use of purified cannabidiol for children with treatment-resistant developmental and epileptic encephalopathies. Epilepsy & Behavior. https://doi.org/10.1016/j.yebeh.2025.110590

Vancouver

Reyes Valenzuela G, Espeche A, Fortini S, Gamboni B, Adi J, Semprino M, et al. A multicenter study on the use of purified cannabidiol for children with treatment-resistant developmental and epileptic encephalopathies. Epilepsy & Behavior. 2025. doi:10.1016/j.yebeh.2025.110590

BibTeX
@article{ReyesValenzuela2025,
  author = {Reyes Valenzuela, Gabriela and Espeche, Alberto and Fortini, Sebastian and Gamboni, Beatriz and Adi, Javier and Semprino, Marco and Fasulo, Lorena and Galicchio, Santiago and Cachia, Pedro and Chacón, Santiago and Calvo, Agustin and Beltran, Lucas and Bautista, Claudia and Caraballo, Roberto H},
  title = {A multicenter study on the use of purified cannabidiol for children with treatment-resistant developmental and epileptic encephalopathies},
  journal = {Epilepsy & Behavior},
  year = {2025},
  doi = {10.1016/j.yebeh.2025.110590}
}
Kostenlos starten →